Bionano Genomics (BNGO) to Release Quarterly Earnings on Wednesday

Bionano Genomics (NASDAQ:BNGO) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Tuesday, March 5th. The company reported ($0.96) EPS for the quarter. The business had revenue of $10.72 million for the quarter. Bionano Genomics had a negative net margin of 643.74% and a negative return on equity of 103.68%. On average, analysts expect Bionano Genomics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bionano Genomics Trading Up 0.4 %

Shares of BNGO traded up $0.00 during mid-day trading on Tuesday, reaching $1.00. 136,709 shares of the company’s stock traded hands, compared to its average volume of 1,556,871. Bionano Genomics has a 12 month low of $0.71 and a 12 month high of $8.20. The stock’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.29. The company has a current ratio of 1.40, a quick ratio of 1.17 and a debt-to-equity ratio of 0.04.

Analyst Ratings Changes

Separately, Scotiabank lowered their target price on Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating for the company in a report on Thursday, March 7th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.